Metabolic Signaling and the Epigenome

September 13th - 15th, 2018

Co-Chairs:
Julie-Aurore Losman, MD, PhD, Dana-Farber Cancer Institute, Boston, MA
Kathryn Wellen, PhD, University of Pennsylvania, Philadelphia, PA

Participants:
Nabeel Bardeesy, PhD, Massachusetts General Hospital, Boston, MA
Bryce Carey, PhD, Rockefeller University, New York, NY
John Denu, PhD, University of Wisconsin, Madison, WI
Andrew Dillin, PhD, University of California, Berkeley, Berkeley, CA
Lydia Finley, PhD, Memorial Sloan Kettering Cancer Center, New York, NY
Christian Frezza, MSc, PhD, University of Cambridge, Cambridge, England
Lucy Godley, Md, PhD, University of Chicago, Chicago, IL
Russell Jones, PhD, McGill University, Montreal, Quebec
William Kaelin, Jr. IV MD, Dana-Farber Cancer Institute, Boston, MA
Mei Kong, PhD, City of Hope, Duarte, CA
Jason Locasale, PhD, Duke University, Durham, NC
Oliver G. McDonald, MD, PhD, Vanderbilt University, Nashville, TN
Jordan Meier, PhD, National Cancer Institute, Frederick, MD
Joshua D. Rabinowitz, Princeton University, Princeton NJ
Martine Roussel, PhD, St. Jude Children’s Research Hospital, Memphis, TN
Paolo Sassone-Corsi, PhD, University of California, Irvine, Irvine, CA
Karen Vousden, PhD, The Francis Crick Institute, London, England

Scholars:
Andrew Aguirre, MD, PhD, Dana Farber Cancer Institute, Boston, MA
Donita Brady, PhD, University of Pennsylvania, Philadelphia, PA
Mara Sherman, PhD, Oregon Health & Sciences University, Portland, OR
W. Clay Gustafson, PhD, University of California, San Francisco, CA


Program Description:

Metabolic reprogramming and epigenetic deregulation have both emerged as hallmark features of cancer cells. Although cancer epigenetics and cancer metabolism have been largely viewed as distinct fields, there is a growing appreciation that the metabolic and epigenetic states of cells are highly intertwined. Metabolic programs determine the abundance of key metabolic intermediates such as methyl and acetyl donors that are substrates for the epigenetic enzymes that covalently modify histones and DNA. Conversely, epigenetic programs regulate the expression of metabolic genes, thereby altering the metabolome. As such, epigenetic regulators are highly responsive to metabolic cues and vice versa. In cancer in particular, metabolic signaling to the epigenome plays a critical role in tumorigenesis by coordinating gene expression programs and cellular differentiation, energy supplies, proliferation, and apoptosis. Understanding the links between metabolism and epigenetics has the potential to identify novel molecular targets to treat cancer.

The 2018 Forum on Metabolic Signaling and the Epigenome will bring together current and emerging leaders whose work bridges the metabolism-epigenetics interface to discuss their work and to explore its potential as a novel area for therapeutic intervention.